vs

Side-by-side financial comparison of UiPath, Inc. (PATH) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.

Royalty Pharma plc is the larger business by last-quarter revenue ($622.0M vs $411.1M, roughly 1.5× UiPath, Inc.). UiPath, Inc. runs the higher net margin — 48.4% vs 34.4%, a 13.9% gap on every dollar of revenue. On growth, UiPath, Inc. posted the faster year-over-year revenue change (15.9% vs 4.8%). Over the past eight quarters, Royalty Pharma plc's revenue compounded faster (4.6% CAGR vs 0.7%).

UiPath Inc. is a global software company that develops artificial intelligence (AI) and agentic automation and orchestration software. The company's software enables the building and orchestration of AI agents to automate complex processes and workflows.

Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.

PATH vs RPRX — Head-to-Head

Bigger by revenue
RPRX
RPRX
1.5× larger
RPRX
$622.0M
$411.1M
PATH
Growing faster (revenue YoY)
PATH
PATH
+11.1% gap
PATH
15.9%
4.8%
RPRX
Higher net margin
PATH
PATH
13.9% more per $
PATH
48.4%
34.4%
RPRX
Faster 2-yr revenue CAGR
RPRX
RPRX
Annualised
RPRX
4.6%
0.7%
PATH

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric
PATH
PATH
RPRX
RPRX
Revenue
$411.1M
$622.0M
Net Profit
$198.8M
$214.2M
Gross Margin
83.3%
Operating Margin
3.2%
62.4%
Net Margin
48.4%
34.4%
Revenue YoY
15.9%
4.8%
Net Profit YoY
1966.2%
2.9%
EPS (diluted)
$0.37
$0.49

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PATH
PATH
RPRX
RPRX
Q4 25
$411.1M
$622.0M
Q3 25
$361.7M
$609.3M
Q2 25
$356.6M
$578.7M
Q1 25
$423.6M
$568.2M
Q4 24
$354.7M
$593.6M
Q3 24
$316.3M
$564.7M
Q2 24
$335.1M
$537.3M
Q1 24
$405.3M
$568.0M
Net Profit
PATH
PATH
RPRX
RPRX
Q4 25
$198.8M
$214.2M
Q3 25
$1.6M
$288.2M
Q2 25
$-22.6M
$30.2M
Q1 25
$51.8M
$238.3M
Q4 24
$-10.7M
$208.2M
Q3 24
$-86.1M
$544.0M
Q2 24
$-28.7M
$102.0M
Q1 24
$33.9M
$4.8M
Gross Margin
PATH
PATH
RPRX
RPRX
Q4 25
83.3%
Q3 25
82.2%
Q2 25
82.1%
Q1 25
84.8%
Q4 24
82.0%
Q3 24
80.0%
Q2 24
83.5%
Q1 24
86.8%
Operating Margin
PATH
PATH
RPRX
RPRX
Q4 25
3.2%
62.4%
Q3 25
-5.6%
70.1%
Q2 25
-4.6%
36.3%
Q1 25
7.9%
94.0%
Q4 24
-12.2%
60.9%
Q3 24
-32.7%
Q2 24
-14.8%
50.2%
Q1 24
3.7%
-13.0%
Net Margin
PATH
PATH
RPRX
RPRX
Q4 25
48.4%
34.4%
Q3 25
0.4%
47.3%
Q2 25
-6.3%
5.2%
Q1 25
12.2%
41.9%
Q4 24
-3.0%
35.1%
Q3 24
-27.2%
96.3%
Q2 24
-8.6%
19.0%
Q1 24
8.4%
0.8%
EPS (diluted)
PATH
PATH
RPRX
RPRX
Q4 25
$0.37
$0.49
Q3 25
$0.00
$0.67
Q2 25
$-0.04
$0.07
Q1 25
$0.09
$0.55
Q4 24
$-0.02
$0.46
Q3 24
$-0.15
$1.21
Q2 24
$-0.05
$0.23
Q1 24
$0.07
$0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PATH
PATH
RPRX
RPRX
Cash + ST InvestmentsLiquidity on hand
$1.4B
$618.7M
Total DebtLower is stronger
$9.0B
Stockholders' EquityBook value
$1.9B
$9.7B
Total Assets
$2.9B
$19.6B
Debt / EquityLower = less leverage
0.92×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PATH
PATH
RPRX
RPRX
Q4 25
$1.4B
$618.7M
Q3 25
$1.4B
$938.9M
Q2 25
$1.6B
$631.9M
Q1 25
$1.6B
$1.1B
Q4 24
$1.6B
$929.0M
Q3 24
$1.7B
$950.1M
Q2 24
$1.9B
$1.8B
Q1 24
$1.9B
$843.0M
Total Debt
PATH
PATH
RPRX
RPRX
Q4 25
$9.0B
Q3 25
$8.9B
Q2 25
$8.0B
Q1 25
$7.6B
Q4 24
$7.6B
Q3 24
$7.6B
Q2 24
$7.6B
Q1 24
$6.1B
Stockholders' Equity
PATH
PATH
RPRX
RPRX
Q4 25
$1.9B
$9.7B
Q3 25
$1.7B
$9.6B
Q2 25
$1.7B
$9.5B
Q1 25
$1.8B
$9.8B
Q4 24
$1.7B
$10.3B
Q3 24
$1.8B
$10.3B
Q2 24
$2.0B
$9.8B
Q1 24
$2.0B
$9.9B
Total Assets
PATH
PATH
RPRX
RPRX
Q4 25
$2.9B
$19.6B
Q3 25
$2.6B
$19.3B
Q2 25
$2.6B
$18.3B
Q1 25
$2.9B
$17.6B
Q4 24
$2.7B
$18.2B
Q3 24
$2.7B
$18.0B
Q2 24
$2.8B
$17.7B
Q1 24
$3.0B
$16.1B
Debt / Equity
PATH
PATH
RPRX
RPRX
Q4 25
0.92×
Q3 25
0.93×
Q2 25
0.84×
Q1 25
0.78×
Q4 24
0.74×
Q3 24
0.74×
Q2 24
0.78×
Q1 24
0.62×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PATH
PATH
RPRX
RPRX
Operating Cash FlowLast quarter
$28.3M
$827.1M
Free Cash FlowOCF − Capex
$25.1M
FCF MarginFCF / Revenue
6.1%
Capex IntensityCapex / Revenue
0.8%
Cash ConversionOCF / Net Profit
0.14×
3.86×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PATH
PATH
RPRX
RPRX
Q4 25
$28.3M
$827.1M
Q3 25
$41.6M
$702.6M
Q2 25
$119.0M
$364.0M
Q1 25
$146.1M
$596.1M
Q4 24
$28.1M
$742.5M
Q3 24
$46.4M
$703.6M
Q2 24
$100.0M
$658.2M
Q1 24
$145.6M
$664.6M
Free Cash Flow
PATH
PATH
RPRX
RPRX
Q4 25
$25.1M
Q3 25
Q2 25
$106.2M
Q1 25
$138.7M
Q4 24
$23.2M
Q3 24
$45.0M
Q2 24
$98.8M
Q1 24
$141.8M
FCF Margin
PATH
PATH
RPRX
RPRX
Q4 25
6.1%
Q3 25
Q2 25
29.8%
Q1 25
32.7%
Q4 24
6.5%
Q3 24
14.2%
Q2 24
29.5%
Q1 24
35.0%
Capex Intensity
PATH
PATH
RPRX
RPRX
Q4 25
0.8%
Q3 25
0.0%
Q2 25
3.6%
Q1 25
1.7%
Q4 24
1.4%
Q3 24
0.4%
Q2 24
0.4%
Q1 24
0.9%
Cash Conversion
PATH
PATH
RPRX
RPRX
Q4 25
0.14×
3.86×
Q3 25
26.25×
2.44×
Q2 25
12.06×
Q1 25
2.82×
2.50×
Q4 24
3.57×
Q3 24
1.29×
Q2 24
6.45×
Q1 24
4.29×
139.10×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PATH
PATH

Subscription Services$247.6M60%
License$150.0M36%
Professional Services And Other$13.5M3%

RPRX
RPRX

Financial Royalty Assets$592.4M95%
Royalty Income Other$29.6M5%

Related Comparisons